Fred B. Craves - Dec 3, 2021 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Signature
/s/ Fred B. Craves
Stock symbol
MDGL
Transactions as of
Dec 3, 2021
Transactions value $
$0
Form type
4
Date filed
12/7/2021, 03:30 PM
Previous filing
Jun 21, 2021
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Other $0 -750K -33.19% $0.00 1.51M Dec 3, 2021 See Footnotes F1, F2, F7
transaction MDGL Common Stock Other $0 -49.7K -100% $0.00* 0 Dec 3, 2021 See Footnotes F1, F3, F7
transaction MDGL Common Stock Other $0 -24.2K -95.04% $0.00 1.26K Dec 3, 2021 See Footnotes F1, F4, F7
holding MDGL Common Stock 364K Dec 3, 2021 Direct F8
holding MDGL Common Stock 15K Dec 3, 2021 See Footnote F5
holding MDGL Common Stock 90K Dec 3, 2021 See Footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.
F2 These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
F3 These securities were held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities previously held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
F4 These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
F5 Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
F6 Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
F7 Represents transfers, without the payment of any consideration, to their partners and employees.
F8 Includes 46,779 shares previously reported as indirectly held.